REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
23/02/2026
Voltar para busca
Dado oficial do USPTO
NUMAB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
NUMAB
ST13
US500000079266778Classe
1, 5, 42, 44
Pedido
79266778
Registro
6274672
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
24/02/2026
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
28/11/2018
Data de registro
23/02/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/02/2021
Última transação
24/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
CH
Examinador
KNIGHT, TROY FRANK
Unidade examinadora
L70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Numab Therapeutics AG
Numab Therapeutics AG
Numab Innovation AG
Representantes
Dennis S. Prahl Ladas & Parry LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalsbiochemicalsbiological preparations and enzymes from biotechnological processes for use in industry and science; chemicalsbiochemicalsbiological preparations and enzymesantibodies and antibody fragmentsfrom biotechnological processesfor development and manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof; biological products comprising monoclonal antibodies and/or derivatives thereofantibodies and antibody fragments for use in laboratoriesdiagnosis and analysis for scientific and research purposes; chemical and biochemical additivescarriers and substances for manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof
Classe 5
Pharmaceutical comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases and other pathologiestreatable or improvable through use of antibodies that bind toactivate or block the target antigens; medicines comprising monoclonal antibodies and/or derivatives thereof for human medicine for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; medicines comprising monoclonal antibodies and/or derivatives thereof for veterinary use for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; chemical pharmaceutical products comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; diagnostic preparations for medical use comprising monoclonal antibodies and/or derivatives thereof; chemical preparations comprising monoclonal antibodies and/or derivatives thereof for pharmaceutical use for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases; chemical preparations for veterinary use comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancerleukemialymphomasinflammatory diseasesimmunological diseases
Classe 42
Research and development services in the field of pharmaceutical preparationsbiotechnologyantibodies and antibody fragmentsproteinsmicro-organisms and cells for therapeutic purposes; research services with respect to pharmaceutical preparationsbiotechnologyantibody therapy and gene therapy; scientific and technological services of a chemical and molecular biological laboratory; researchproduct development and quality control services in the field of pharmacymedical diagnostics and medical therapy; research services in the field of chemistry and biology; industrial analysis and research services in the field of pharmacymedical diagnosismedical therapy; research and development services for antibody products for therapeutic purposes; conducting and preparing chemicalbiochemical and biotechnological analysis and research
Classe 44
Medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the fields of immuno-oncologyoncology and immunology; provision of medical information; Medical service featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the nature of preparation and administration of medicines in the field of immuno-oncologyoncology and immunology; advice in connection with dietetics and nutrition; advice with respect to health and provision of health information in the fields of immuno-oncologyoncology and immunology; veterinary services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; hygienic and beauty care for humans and animals; provision of information on diagnosticprophylactic and therapeutic properties of drugs in the fields of immuno-oncologyoncology and immunology
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
31/12/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
27/08/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/06/2021
CHLD
CHANGE OF OWNER RECEIVED FROM IB
06/06/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/05/2021
FIMP
FINAL DISPOSITION PROCESSED
26/05/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
23/05/2021
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
01/03/2021
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
28/02/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
23/02/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/12/2020
PUBO
PUBLISHED FOR OPPOSITION
08/12/2020
GPNX
NOTIFICATION PROCESSED BY IB
06/12/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/11/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/11/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/11/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/10/2020
ALIE
ASSIGNED TO LIE
13/10/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/09/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/03/2020
GNRT
NON-FINAL ACTION E-MAILED
06/03/2020
CNRT
NON-FINAL ACTION WRITTEN
06/03/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/02/2020
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
14/02/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/02/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/02/2020
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
07/02/2020
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
14/11/2019
RFNT
REFUSAL PROCESSED BY IB
19/10/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/09/2019
RFRR
REFUSAL PROCESSED BY MPU
28/09/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/09/2019
CNRT
NON-FINAL ACTION WRITTEN
17/09/2019
MAFR
APPLICATION FILING RECEIPT MAILED
17/09/2019
DOCK
ASSIGNED TO EXAMINER
13/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/09/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/09/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NUMAB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.